乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究*

doi:10.3969/j.issn.1672-5069.2022.01.019

摘要/Abstract

摘要： 目的研究乙型肝炎肝硬化并发肝性脑病(HE)患者血氨水平变化与认知障碍程度的关系。方法 2018年3月～2020年9月我院诊治的乙型肝炎肝硬化并发HE患者94例,根据临床和蒙特利尔认知评估量表(MoCA)评分评估认知障碍程度。常规检测血氨,计算计算胰岛素抵抗指数(HOMA-IR)。采用Logistic多因素回归模型分析发生昏迷的影响因素,建立预测模型。应用MedCalc1 5.1统计学软件绘制受试者工作特征曲线(ROC),计算曲线下面积(AUC),判断模型预测发生昏迷的效能。结果在本组94例患者中,发生昏迷32例(34.0%);昏迷组血氨水平为(120.7±18.2)μmol/L,显著高于轻中度认知障碍者【(76.4±18.3)μmol/L,P<0.05】;昏迷组MoCA评分为(13.7±1.2)分,显著低于轻中度认知障碍者【(18.2±2.9)分,P<0.05】;昏迷组视空间执行能力、命名、注意、语言、抽象、延迟记忆和定向力各维度评分分别为(1.5±0.6)分、(1.6±0.7)分、(2.1±1.0)分、(1.7±0.6)分、(0.9±0.3)分、(2.0±0.8)分和(4.9±0.8)分,显著低于轻中度认知障碍者【分别为(2.7±1.0)分、(2.2±0.9)分、(3.4±1.2)分、(2.5±0.7)分、(1.5±0.4)分、(4.4±1.1)分和(5.4±1.0)分,P <0.05】;乙型肝炎肝硬化并发HE患者血氨水平与MoCA评分呈显著负相关(r=-0.511,P<0.001);Logistic多因素分析结果显示血氨(β=-0.529,95%CI=0.432～0.803,P<0.001)、高敏C反应蛋白 (β=-0.345,95%CI=0.518～0.968,P=0.030)和胰岛素抵抗指数(β=-0.761,95%CI=0.289～0.755,P=0.002)是患者发生昏迷的独立影响因素;根据Logistic多因素分析结果建立预测模型P=1/【1+e^{(0.242+0.980X1+0.529X2+0.345X3+0.761X4)}】,经受试者工作曲线(ROC)分析显示该模型判断患者发生昏迷的曲线下面积(AUC)为0.843(SE=0.042,95%CI=0.760～0.926,P<0.001),其敏感度为0.806,特异度为0.781。结论乙型肝炎肝硬化并发HE患者认知功能与血氨水平密切相关,监测血氨水平变化有助于预测发生昏迷的风险。

关键词: 肝硬化, 肝性脑病, 血氨, 认知障碍, 诊断

Abstract: Objective The aim of this study was to investigate serum ammonia level changes and itscorrelation to cognitive impairment (CI) in patients with hepatitis B cirrhosis and hepatic encephalopathy (HE). Methods There were 94 patients with hepatitis B liver cirrhosis and HE encountered in our hospital between March 2018 and September 2020, the cognitive impairment was estimated by Montreal cognitive assessment scale (MoCA) and homeostasis model assessment-insulin resistance (HOMA-IR) wascalculated. The Logistic regression model was applied to analyze the risk factors impacting cognitive impairment, and the area under receiver operating characteristic (AUC) was used to predict the occurrence of hepatic coma. Results There were 32 cases of hepatic coma out of 94 patients (34.0%) in our series; the blood ammonia level in patients with hepatic coma was (120.7±18.2) μmol/L, significantly higher than [(76.4±18.3)μmol/L,P<0.05], and the total score of MoCA was (13.7±1.2), significantly lower than [(18.2±2.9), P<0.05] in patients with mild to moderate CI; the scores of visuospatial executive ability, naming, attention, language, abstraction, delayed memory and orientation were (1.5±0.6),(1.6±0.7),(2.1±1.0),(1.7±0.6),(0.9±0.3),(2.0±0.8)and (4.9±0.8), all significantly lower than [(2.7±1.0),(2.2±0.9),(3.4±1.2),(2.5±0.7),(1.5±0.4),(4.4±1.1) and (5.4±1.0),respectively, P<0.05] in patients with mild to moderate CI; there was a significant negative correlation between serum ammonia levels and total MoCA scores in patients with hepatitis B cirrhosis and HE (r=-0.511, P<0.001); the Logistic multivariate analysis showed that blood ammonia (β=-0.529,95% CI=0.432-0.803, P<0.001), serum high sensitivity C-reactive protein levels (β= -0.345,95% CI=0.518-0.968,P =0.030) and HOMA-IR (β=-0.761,95% CI=0.289-0.755, P=0.002) were the independent influencing factors for patients with hepatic coma; the performance of our established prediction model: P=1/[1+e^{(0.242+0.980X1+0.529X2+0.345X3+0.761X4)}] was excellent with the AUC of 0.843 (SE=0.042,95%CI=0.760-0.926,P<0.001), and the sensitivity and specificity of 0.806 and 0.781, respectively in predicting the occurrence of hepatic coma. Conclusion The cognitive functions of patients with hepatitis B cirrhosis and HE is closely related to blood ammonialevels, and it might be helpful to predict the risk of hepatic coma by monitoring blood ammonia levels.

Key words: Liver cirrhosis, Hepatic encephalopathy, Blood ammonia, Cognitive impairment, Diagnostic trial

李艳乐, 刘笑宇, 姚建宁, 王春峰, 张连峰, 张学秀. 乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 74-78.

Li Yanle, Liu Xiaoyu, Yao Jianning, et al. Serum ammonia level changes and its correlation to cognitive impairment in patients with hepatitis B cirrhosis and hepatic encephalopathy[J]. Journal of Practical Hepatology, 2022, 25(1): 74-78.

参考文献

[1] Moratalla A, Ampuero J, Bellot P, et al. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Liver Int, 2017,37(2):212-223.
[2] Sobczyk K, Jordens M S, Karababa A, et al. Ephrin/ephrin receptor expression in ammonia-treated rat astrocytes and in human cerebral cortex in hepatic encephalopathy. Neurochem Res, 2015,40(2):274-283.
[3] Haj M, Rockey D C. Ammonialevels do not guide clinical management of patients with hepatic encephalopathy caused by cirrhosis. Am J Gastroenterol,2020, 115(5):723-728.
[4] Mohammadian F,Firouzjaei M A, Haghani M, et al. Inhibition of inflammation is not enough for recovery of cognitive impairment in hepatic encephalopathy: Effects of minocycline and ibuprofen. Brain Res Bull, 2019,149(7):96-105.
[5] Ganai A A, Husain M. Genisteinalleviates neuroinflammation and restores cognitive function in rat model of hepatic encephalopathy: underlying mechanisms. Mol Neurobiol, 2018,55(2):1762-1772.
[6] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版).实用肝脏病杂志,2020,23(1):9-32.
[7] 中华医学会肝病学分会.肝硬化肝性脑病诊疗指南.中华肝脏病杂志,2018,26(10):721-736.
[8] 翟雅莉,钞秋玲,沈明志, 等.修订后的MoCA量表在老年人轻度认知功能障碍诊断中的信度和效度分析.中华神经医学杂志,2013,12(2):179-182.
[9] Bouchara A, Yi D, Pastural M, et al. Serum levels of the adipokine zinc-alpha2-glycoprotein (ZAG) predict mortality in hemodialysis patients. KidneyInt, 2018, 94(5):983-992.
[10] Jaeger V, Demorrow S, Mcmillin M.The direct contribution of astrocytes and microglia to the pathogenesis of hepatic encephalopathy. J Clin Hepatol,2019, 7(4):352-361.
[11] Görg B, Karababa A,Schutz E, et al. O-glcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy. J Hepatol, 2019, 71(5):930-941.
[12] Senzolo M, Zarantonello L, Formentin C, et al. Predictive value of induced hyperammonaemia and neuropsychiatric profiling in relation to the occurrence of post-TIPS hepatic encephalopathy. Metab Brain Dis, 2019,34(6):1803-1812.
[13] Bucsics T, Hoffmann S,Grunberger J, et al. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver Int, 2018,38(6):1036-1044.
[14] Hertz L,Peng L,Song D. Ammonia, like K⁺, stimulates the Na⁺, K⁺, 2Cl cotransporter NKCC1 and the Na⁺,K⁺-ATPase and interacts with endogenous ouabain in astrocytes. Neurochem Res, 2015,40(2):241-257.
[15] Bellaver B,Souza D G, Souza D O, et al. Hippocampal astrocyte cultures from adult and aged rats reproduce changes in glial functionality observed in the aging brain.Mol Neurobiol, 2017,54(4):2969-2985.
[16] Liu X Y, Ma L N, Yan T T, et al. Combined detection of liver stiffness and C-reactive protein in patients with hepatitis B virus-related liver cirrhosis, with and without hepatocellular carcinoma. Mol Clin Oncol, 2016,4(4):587-590.
[17] 侯玉丽,高梦丹,郭鸿雁,等. 白蛋白-胆红素指数与血氨联合检测对肝硬化并发HE的诊断价值评估.中华医学杂志,2018,98(2):127-131.
[18] Packard R R S. Maddahi J. Regadenoson-induced hyperemia for absolute myocardial blood flow quantitation by 13 N-ammonia PET and detection of cardiac allograft vasculopathy. J Nucl Cardiol, 2017,24(4):1145-1148.
[19] 姬将,赵超云,刘译阳,等.轻微型肝性脑病患者认知功能障碍与脑区低频振幅改变的相关性研究.中华神经医学杂志,2020,19(11):1109-1115.
[20] Zhuge W, Zhuge Q, Wang W, et al. Hydrogen sulphide ameliorates dopamine induced astrocytic inflammation and neurodegeneration in minimal hepatic encephalopathy. J Cell Mol Med,2020,24(23):13634-13647.
[21] Harputluoglu M,Temel I,Demirel U, et al. Methylprednisolone prevents bacterial translocation in thioacetamide-induced liver failure in rats. Turk J Gastroenterol,2017,28(5):394-400.
[22] So A,Sakaguchi K,Okada Y, et al. Relation between HOMA-IR and insulin sensitivity index determined by hyperinsulinemic-euglycemic clamp analysis during treatment with a sodium-glucose cotransporter 2 inhibitor.Endocr J,2020,67(5):501-507.

乙型肝炎肝硬化并发肝性脑病患者血氨水平与认知障碍关系研究^*

Serum ammonia level changes and its correlation to cognitive impairment in patients with hepatitis B cirrhosis and hepatic encephalopathy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	杨艳, 刘婷, 戴琳, 努丽曼姑·麦麦提, 刘环. 声触诊弹性成像检测肝脾硬度诊断慢性乙型肝炎患者肝纤维化效能分析^*[J]. 实用肝脏病杂志, 2022, 25(2): 183-186.
[2]	黄平, 曾霞, 张亚萍, 毛加丽. 肝静脉波形分型联合肝脏超声半定量评分对慢性乙型肝炎患者肝纤维化程度评估价值研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 187-190.
[3]	曲颖, 蔡晓波, 张启迪, 陆伦根. 体检人群血清M2型抗线粒体抗体流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(2): 203-206.
[4]	郑小勤, 徐辉, 李丽, 靳华, 汪晓军, 勾春燕. 家族聚集性原发性胆汁性肝硬化患者临床特征分析[J]. 实用肝脏病杂志, 2022, 25(2): 207-210.
[5]	曾议, 李国, 李红翠, 彭雅松, 田峰, 王小军. 熊去氧胆酸治疗原发性胆汁性胆管炎患者疗效及对血清Nrf2和HO-1水平的影响[J]. 实用肝脏病杂志, 2022, 25(2): 211-214.
[6]	郝玉婷, 林洁, 秦杰. 长期接受恩替卡韦治疗的乙型肝炎肝硬化患者血清水通道蛋白8和水通道蛋白9变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(2): 243-246.
[7]	王本贤, 李伟, 李东生, 李华. 腹水浓缩回输联合抗感染治疗失代偿期乙型肝炎肝硬化患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 247-250.
[8]	刘松涛, 刘梅, 渠亚超, 李瑞利, 邵晨, 闾军. 4例原发性肝脏神经内分泌肿瘤临床分析及文献复习[J]. 实用肝脏病杂志, 2022, 25(2): 251-254.
[9]	余涛, 付路路, 陈方, 田园. 超声造影灌注时相分析在肝硬化背景下对肝脏增生结节的诊断价值[J]. 实用肝脏病杂志, 2022, 25(2): 267-270.
[10]	何福亮, 马琳, 李悦榕, 王宇, 王民, 冯丽娟, 张冠华, 欧晓娟, 刘福全, 贾继东. 非肝硬化性门脉高压的临床诊断[J]. 实用肝脏病杂志, 2022, 25(1): 1-4.
[11]	张裕, 刘福全. 经颈静脉门体静脉分流术精准技术与合理分流道的建立^*[J]. 实用肝脏病杂志, 2022, 25(1): 5-8.
[12]	陈靖, 朱月永. 无创诊断肝硬化门静脉高压症:血清标志物还是影像学检查？[J]. 实用肝脏病杂志, 2022, 25(1): 9-12.
[13]	叶超, 李文渊, 李磊, 陈思, 李未, 张开光. 一组不明原因的肝损害患者肝组织病理学诊断研究^*[J]. 实用肝脏病杂志, 2022, 25(1): 38-41.
[14]	徐艳, 于秉楠, 武剑. 自身免疫性肝炎和原发性胆汁性肝硬化患者自身免疫性甲状腺疾病流行率调查^*[J]. 实用肝脏病杂志, 2022, 25(1): 42-45.
[15]	周晓永, 白阳秋, 杨惠, 张炳勇, 曲波. 原发性胆汁性胆管炎患者血清甲状腺激素水平和抗甲状腺抗体阳性率变化^*[J]. 实用肝脏病杂志, 2022, 25(1): 46-49.